NYSE:CNMD - CONMED Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $131.75
  • Forecasted Upside: -4.72 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$138.27
▲ +2.86 (2.11%)

This chart shows the closing price for CNMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CONMED Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNMD

Analyst Price Target is $131.75
▼ -4.72% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for CONMED in the last 3 months. The average price target is $131.75, with a high forecast of $175.00 and a low forecast of $92.00. The average price target represents a -4.72% upside from the last price of $138.27.

This chart shows the closing price for CNMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in CONMED. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2021BarclaysInitiated CoverageOverweight$175.00Low
4/29/2021Piper SandlerBoost Price TargetPositive ➝ Overweight$145.00 ➝ $160.00High
1/28/2021Piper SandlerBoost Price TargetOverweight$95.00 ➝ $145.00Low
7/30/2020Stifel NicolausBoost Price TargetBuy$82.00 ➝ $100.00High
7/30/2020SVB LeerinkBoost Price TargetMarket Perform$82.00 ➝ $92.00High
7/29/2020Piper SandlerBoost Price TargetOverweight$90.00 ➝ $95.00Medium
4/30/2020SVB LeerinkReiterated RatingMarket PerformLow
4/30/2020Stifel NicolausBoost Price TargetBuy$65.00 ➝ $82.00Medium
4/30/2020Piper SandlerLower Price TargetOverweight$110.00 ➝ $90.00Medium
4/30/2020Needham & Company LLCReiterated RatingHoldMedium
4/23/2020JPMorgan Chase & Co.Lower Price TargetOverweight$136.00 ➝ $76.00Medium
4/14/2020BarclaysReiterated RatingBuy$110.00Medium
3/10/2020Piper SandlerLower Price Target$130.00 ➝ $110.00High
3/10/2020Needham & Company LLCReiterated RatingHoldHigh
11/26/2019Needham & Company LLCDowngradeBuy ➝ HoldHigh
11/12/2019JPMorgan Chase & Co.Initiated CoverageOverweight$136.00Medium
10/31/2019Needham & Company LLCBoost Price TargetBuy$111.00 ➝ $115.00High
10/4/2019Needham & Company LLCBoost Price TargetBuy$101.00 ➝ $111.00Medium
8/22/2019Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$88.00 ➝ $110.00High
8/1/2019Stifel NicolausBoost Price TargetBuy$97.00 ➝ $99.00High
8/1/2019BarclaysBoost Price TargetOverweight$96.00 ➝ $105.00High
4/17/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$95.00Medium
4/16/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$87.00 ➝ $94.00High
4/15/2019BarclaysBoost Price TargetOverweight ➝ Overweight$85.00 ➝ $92.00Low
2/27/2019Needham & Company LLCBoost Price TargetBuy$87.00Low
2/19/2019BarclaysInitiated CoverageEqual Weight ➝ Overweight$85.00High
1/23/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$86.00 ➝ $79.00High
10/16/2018BarclaysSet Price TargetEqual Weight ➝ Equal Weight$78.00High
8/30/2018SVB LeerinkBoost Price TargetMarket Perform$76.00 ➝ $81.00Low
8/2/2018Needham & Company LLCBoost Price TargetBuy$73.00 ➝ $83.00High
4/26/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$71.00 ➝ $73.00High
2/1/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$58.00 ➝ $71.00High
11/17/2017Needham & Company LLCReiterated RatingBuy$58.00N/A
11/3/2017KeyCorpReiterated RatingHoldN/A
11/3/2017Piper Jaffray CompaniesReiterated RatingHold$46.00N/A
9/1/2017Needham & Company LLCReiterated RatingBuy$57.00Low
8/25/2017KeyCorpReiterated RatingHoldLow
7/27/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$54.00 ➝ $57.00Low
4/27/2017LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral$50.00 ➝ $48.00High
4/27/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$48.00 ➝ $54.00High
2/2/2017Needham & Company LLCReiterated RatingBuy$48.00N/A
11/23/2016SVB LeerinkReiterated RatingHold ➝ NeutralN/A
11/18/2016Needham & Company LLCBoost Price TargetBuy$49.00 ➝ $53.00N/A
10/28/2016SVB LeerinkReiterated RatingMarket Perform$47.00 ➝ $43.00N/A
7/28/2016SVB LeerinkDowngradeOutperform ➝ Market Perform$56.00 ➝ $47.00N/A
(Data available from 6/22/2016 forward)
CONMED logo
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Read More

Today's Range

Now: $138.27
Low: $135.03
High: $139.45

50 Day Range

MA: $137.04
Low: $128.08
High: $145.09

52 Week Range

Now: $138.27
Low: $65.74
High: $146.95

Volume

149,193 shs

Average Volume

273,132 shs

Market Capitalization

$4.02 billion

P/E Ratio

354.54

Dividend Yield

0.59%

Beta

1.54

Frequently Asked Questions

What sell-side analysts currently cover shares of CONMED?

The following Wall Street sell-side analysts have issued research reports on CONMED in the last twelve months: Barclays PLC, Piper Sandler, Stifel Nicolaus, and SVB Leerink LLC.
View the latest analyst ratings for CNMD.

What is the current price target for CONMED?

4 Wall Street analysts have set twelve-month price targets for CONMED in the last year. Their average twelve-month price target is $131.75, suggesting a possible downside of 4.7%. Barclays PLC has the highest price target set, predicting CNMD will reach $175.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $92.00 for CONMED in the next year.
View the latest price targets for CNMD.

What is the current consensus analyst rating for CONMED?

CONMED currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CNMD will outperform the market and that investors should add to their positions of CONMED.
View the latest ratings for CNMD.

What other companies compete with CONMED?

How do I contact CONMED's investor relations team?

CONMED's physical mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The company's listed phone number is 315 797 8375. The official website for CONMED is www.conmed.com.